Retatrutide, explained

The most talked-about unapproved weight-loss drug in the world adds a third hormone receptor to the semaglutide formula. What the one mid-stage trial showed, and why that is not yet the same as a known drug.

What it is and how it works

Retatrutide takes the incretin idea one receptor further: it activates GLP-1, GIP and the glucagon receptor in a single weekly injection. The glucagon arm is the new part. Glucagon raises energy expenditure and pushes the liver to mobilise fat, which in principle adds a metabolic-rate component to the appetite suppression the other two receptors provide.

It is an investigational drug made by Eli Lilly under the code LY3437943. There is no approved label anywhere, no approved dose and no approved use. Anything sold today under the name is research-grade powder of unverified identity.

What the trials showed

The evidence base is one phase 2 programme, published in 2023, in a few hundred people. The results were the largest ever recorded for an incretin drug, which is why the compound is famous. They are also the whole story: phase 3 is still running, and there is no long-term safety or cardiovascular outcome data.

Risks, and why phase 3 matters

Phase 2 reported the expected dose-dependent nausea and other gastrointestinal effects, plus increases in resting heart rate, a known consequence of glucagon activation. Beyond that, the honest answer is that the safety profile of a triple agonist is not yet characterised. Phase 3 exists to find the effects that a few hundred people cannot reveal, and the gap between a best-in-field phase 2 result and an approved drug is where most abandoned compounds live.

Because it is unapproved, everyone using it now is reconstituting powder themselves at doses extrapolated from a trial they were not in, without monitoring, and generating the safety data privately. For anyone weighing injectable weight loss today, the practical comparison is with the two approved drugs, semaglutide and tirzepatide, which have the outcome data retatrutide does not yet have.

Want the long version? Read the full retatrutide write-up, with sources.

Research use only. A reading aid for the published literature, not medical advice. Talk to a licensed prescriber before starting or stopping any medication.